DNA-histone complex (TNT antigen)

DNA-histone complexes, primarily in the form of nucleosomes, are the fundamental structural units of eukaryotic chromatin, consisting of DNA segments wrapped around histone octamers (Epstein et al., 1988, Cancer Research). In healthy tissues, these complexes are strictly sequestered within the cell nucleus, making them inaccessible to circulating antibodies. However, in the necrotic regions of solid tumors—where cell membrane integrity is lost—these complexes become exposed to the extracellular space (Street et al., 2006, Journal of Clinical Oncology). This phenomenon is exploited by Tumor Necrosis Therapy (TNT), which uses specialized monoclonal antibodies to target these abundant and stable antigens. By binding to DNA-histone complexes in necrotic zones, these antibodies can deliver therapeutic payloads such as radionuclides (e.g., Iodine-131) or cytokines (e.g., IL-12) directly into the tumor microenvironment (Scharfman et al., 2011, Clinical Cancer Research). This strategy aims to treat the surrounding viable tumor cells from within the necrotic core, potentially overcoming issues related to poor vascularization and high interstitial pressure (He et al., 2002, World Journal of Gastroenterology). Clinical applications have focused on aggressive malignancies like glioblastoma multiforme and various advanced solid tumors.

Other names

NucleosomeChromatinNecrotic tumor DNATumor Necrosis Therapy targetDNA-histone complex in necrotic tumor tissue

Targeted delivery of therapeutic agents (radionuclides or cytokines) to the necrotic core of tumors via high-affinity binding to exposed DNA-histone complexes.